TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37209243
Drug: Intraosseous computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous computerized anaesthesia (ICA) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Study: 37209243
Drug: Conventional inferior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inferior alveolar nerve block (IANB) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Study: 37209422
Drug: Technology-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-based training in exposure therapy
Study: 37209421
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment support via free combination NRT at discharge and automated counseling
Study: 37209421
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment support
Study: 37209427
Drug: Ulotaront 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulotaront 25 mg
Study: 37209427
Drug: Ulotaront 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulotaront 50 mg
Study: 37209700
Drug: AAd5 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAd5 (0.1 mL)
Study: 37209700
Drug: IMAd5 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMAd5 (0.3 mL)
Study: 37209700
Drug: Inactivated vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccine (BBIBP-CorV or CoronaVac; 0.5 mL)
Study: 37209893
Drug: Intrauterine balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine balloon tamponade combined with sulprostone infusion
Study: 37209893
Drug: Intrauterine balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine balloon tamponade after sulprostone infusion
Study: 37209996
Drug: Drug Coated
Normalized name: Drug coated stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Coated Balloons (DCBs)
Study: 37210048
Drug: 5-fraction Stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fraction Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART), 50 gray in 5 fractions.
Study: 37210098
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg rimegepant
Study: 37210099
Drug: Valbenazine (≤80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine (≤80 mg, as tolerated)
Study: 37210308
Drug: mRNA-1388 25
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1388 25 μg
Study: 37210308
Drug: mRNA-1388 50
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1388 50 μg
Study: 37210308
Drug: mRNA-1388 100
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1388 100 μg
Study: 37210308
Drug: mRNA-1388 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1388 (all doses)
Study: 37210308
Drug: mRNA-1388 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1388 (50 μg and 100 μg)
Study: 37210741
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 5-µg rS with 50 µg Matrix-M adjuvant
Study: 37210741
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 5-µg rS with 50 µg Matrix-M adjuvant
Study: 37210741
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 25-µg rS with 50 µg Matrix-M adjuvant
Study: 37210742
Drug: Metolazone 5-10
Normalized name: metolazone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone 5-10 mg once daily
Study: 37210887
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy plus a Memory Support Intervention
Study: 37210887
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy as usual
Study: 37211246
Drug: Ziltivekimab 15
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 15 mg and 30 mg
Study: 37211611
Drug: Home-based multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based multicomponent exercise program with weekly telephone supervision from diagnosis until three months post-surgery
Study: 37212315
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatment arms (AVT04, US-RP, EU-RP)
Study: 37212651
Drug: Sertraline (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25-100 mg)
Study: 37212686
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus S-1 combined intraperitoneal and intravenous paclitaxel
Study: 37212970
Drug: Heavy lifting
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy lifting strength training (HLST) program, 12 weeks, twice weekly, lifting 80-90% of 1 repetition maximum (1RM)
Study: 37213102
Drug: Danuglipron 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron 120 mg twice daily
Study: 37213102
Drug: Danuglipron 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron 80 mg twice daily
Study: 37213122
Drug: Dual thrombolytic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual thrombolytic treatment with 5 mg intravenous alteplase and 40 mg intravenous mutant prourokinase
Study: 37213122
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with 0.9 mg/kg intravenous alteplase
Study: 37213907
Drug: Electromagnetic Network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromagnetic Network Targeting Field (ENTF) therapy
Study: 37214210
Drug: MALT1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MALT1 inhibitor
Study: 37214431
Drug: Exogenous DL-beta-hydroxybutyrate
Normalized name: beta-phenyl-DL-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous DL-beta-hydroxybutyrate supplementation, dosage and duration not specified.
Study: 37214450
Drug: vonoprazan-containing triple
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: vonoprazan-containing triple therapy
Study: 37214890
Drug: Strengths-based and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengths-based and community-driven intervention to reduce gun violence, details on dosage and duration not available.
Study: 37215389
Drug: Low-dose prucalopride
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prucalopride (0.04 mg/kg)
Study: 37215389
Drug: High-dose prucalopride
Normalized name: prucalopride
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-dose prucalopride (0.08 mg/kg)
Study: 37215679
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU), supportive counseling and psychoeducation
Study: 37216357
Drug: Short-term antibiotic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term antibiotic treatment (8 weeks in early IOM and 12 weeks in delayed IOM)
Study: 37216357
Drug: Long-term antibiotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antibiotic treatment (12 weeks in early IOM or until fracture healing or implant removal in delayed IOM)
Study: 37216357
Drug: Both short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both short-term and long-term treatments
Study: 37216396
Drug: Vemurafenib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (20 mg/kg) combined with Ara-C (100 mg/m2 every 12 h, days 1-5) and 2-CdA (6 mg/m2 per day, days 1-5) followed by mono 2-CdA.
Study: 37216921
Drug: Crinecerfont (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinecerfont (50 mg twice daily for 14 days)
Study: 37217183
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (DMF) therapy
Study: 37217243
Drug: IDO/PD-L1 targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO/PD-L1 targeting peptide vaccine combined with nivolumab (NCT03047928)
Study: 37217243
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients in cohort B receiving anti-PD-1 therapy with peptide vaccine)
Study: 37217273
Drug: TAS5315 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS5315 4 or 2 mg once daily for 12 weeks
Study: 37217882
Drug: Driving pressure-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Driving pressure-guided ventilation (titration group)
Study: 37217911
Drug: Implant insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant insertion with internal connection implants (Twinfit, Dentaurum, Ispringen, Germany) after piezoelectric implant site preparation.
Study: 37218946
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy guided by pre-RT Cho/NAA twice normal volume (Cho/NAA ≥ 2x)
Study: 37219686
Drug: Tovorafenib administered
Normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tovorafenib administered once every other day (Q2D) at RP2D of 200 mg
Study: 37219686
Drug: Tovorafenib administered
Normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tovorafenib administered once weekly (QW) at RP2D of 600 mg
Study: 37219865
Drug: Clenbuterol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenbuterol (40 μg daily increased to 80 μg twice daily)
Study: 37220015
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment model (baseline population testing with ART by country standard)
Study: 37220119
Drug: Fortetropin® supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortetropin® supplement (FOR-SUPP, n = 12) consuming 19.8 g/d of FOR
Study: 37220130
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser ablation (EVLA) of the incompetent saphenous trunk without tributary treatment
Study: 37220815
Drug: Post-treatment CST
Normalized name: dimethiconol (50000 CST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment CST close to estimated inflection points (217 to 256 μm)
Study: 37220822
Drug: Study medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medications delivery
Study: 37220998
Drug: Tirofiban combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban combined with Aspirin
Study: 37220998
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with Aspirin
Study: 37221177
Drug: Low bolus
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low bolus + low infusion (15 mg + 0.6 mg/min)
Study: 37221177
Drug: High bolus
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bolus + high infusion (25 mg + 1 mg/min)
Study: 37221177
Drug: Low infusion
Normalized name: Solution, Multi Ingredient Topical application Solution [AVEENO POSITIVELY RADIANT MAXGLOW INFUSION DROPS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low infusion (0.6 mg/min)
Study: 37221177
Drug: High infusion
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High infusion (1 mg/min)
Study: 37221407
Drug: In-hospital pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital pharmacotherapy optimization
Study: 37221466
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated DENV3 monovalent vaccine rDEN3Δ30/31-7164
Study: 37222204
Drug: Nivolumab as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab as adjuvant treatment after curative surgery for oesophagal or gastroesophageal junction cancer
Study: 37222204
Drug: Neoadjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunotherapy in dMMR colorectal cancers
Study: 37222252
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (40-60 mg/d)
Study: 37222252
Drug: Combination ISMN-cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination ISMN-cilostazol (40-60 mg/d and 200 mg/d, respectively)
Study: 37222252
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drug (control group)
Study: 37223439
Drug: AXA1125 (33.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXA1125 (33.9 g, administered orally in a liquid suspension twice daily for four weeks)
Study: 37223439
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo administered orally in a liquid suspension twice daily for four weeks)
Study: 37223507
Drug: Low-dose human
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Study: 37223666
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg OD for 14 days
Study: 37223981
Drug: Autonomic Modulation
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Autonomic Modulation Training (AMT) intervention, which includes 1 session of baseline survey measures, 6 weekly sessions of HRV biofeedback training, and 1 follow-up session.
Study: 37224065
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and Ketamine combination
Study: 37224228
Drug: L19TNF in
Normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L19TNF in combination with CCNU
Study: 37224232
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg over 40 minutes, twice per week)
Study: 37224883
Drug: Dual Pathway
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Pathway Inhibition (DPI) with Aspirin plus Vascular-Dose Rivaroxaban
Study: 37224883
Drug: Dual Antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Antiplatelet Therapy (DAPT) with Aspirin (81 mg/qd) plus a P2Y12 inhibitor
Study: 37225045
Drug: sacubitril/valsartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan treatment
Study: 37225248
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (discussion about medication)
Study: 37225265
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg two times a day for 14 days)
Study: 37225266
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling (DN) - ultrasound-guided intramuscular and interfascial DN 8-10 times per pain point or until local twitch responses are no longer elicited, with 30 minutes of indwelling.
Study: 37225266
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency (PRF) - ultrasound-guided intramuscular (0.9% saline 2 mL, 42℃, 2 Hz, 2 min) and interfascial (0.9% saline 5 mL, 42℃, 2 Hz, 2 min) PRF.
Study: 37225267
Drug: Sociodemographic information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sociodemographic information and satisfaction with treatment data collection
Study: 37225552
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy with 20 fractions of radiotherapy
Study: 37225552
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy with 32 fractions of radiotherapy
Study: 37225552
Drug: Concomitant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapies in both 20 and 32 fractions of radiotherapy
Study: 37225710
Drug: Closed-loop neuromodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop neuromodulation treatment
Study: 37226141
Drug: CHAMPS intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHAMPS intervention (CleverCap pill bottle synced to WiseApp)
Study: 37226208
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose frequency (4 times per week for 6 weeks)
Study: 37226208
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose frequency (2 times per week for 12 weeks)
Study: 37226210
Drug: PMHC-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMHC-treatment
Study: 37226281
Drug: Complete Vocal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Vocal Technique voice therapy (CVT-VT)
Study: 37226519
Drug: CTPS1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTPS1 inhibitor (STP938)
Study: 37227176
Drug: SYNB1891 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB1891 monotherapy
Study: 37227176
Drug: SYNB1891 in
Normalized name: SYNB1891
DrugBank: SYNB1891 (DB17541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB1891 in combination with atezolizumab
Study: 37227726
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral rivaroxaban for 7 days (short prophylaxis)
Study: 37227726
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral rivaroxaban for 28 days (long prophylaxis)
Study: 37227726
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral rivaroxaban for both 7 and 28 days
Study: 37227734
Drug: Intraperitoneal olvimulogene
Normalized name: Olvimulogene nanivacirepvec
DrugBank: Olvimulogene nanivacirepvec (DB16268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal olvimulogene nanivacirepvec (Olvi-Vec) followed by platinum-doublet chemotherapy with or without bevacizumab
Study: 37227729
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor (Ticagrelor or Clopidogrel)
Study: 37227729
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no P2Y12 inhibitor)
Study: 37227729
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor
Study: 37227937
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg administered before dialysis session initiation in kidney failure group.
Study: 37228142
Drug: Multifaceted environmental
Normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted environmental control intervention (dynamic light therapy, auditory masking, rationalization of ICU nocturnal patient care activities)
Study: 37229650
Drug: Baricitinib (BARI)
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib (BARI) 4 mg/day for 52 weeks
Study: 37229775
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of elemental oral iron (18.6 mg ferrous sulphate) twice daily for 8 weeks
Study: 37229879
Drug: Carboplatin dosing
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin dosing based on Jelliffe formula
Study: 37229879
Drug: Carboplatin dosing
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin dosing based on MDRD and Cockcroft-Gault formulas
Study: 37230101
Drug: Supplemental dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental dolutegravir (50 mg 12 h later)
Study: 37230366
Drug: Continuous upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous upadacitinib 30 mg
Study: 37230366
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from dupilumab to upadacitinib 30 mg
Study: 37230499
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg) + Mycophenolate mofetil (2 g daily)
Study: 37230499
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Mycophenolate mofetil (2 g daily)
Study: 37230524
Drug: One oral
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral loading dose of 100,000 IU vitamin D
Study: 37231080
Drug: Mescaline 500
Normalized name: Mescaline
DrugBank: Mescaline (DB19083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mescaline 500 mg
Study: 37231080
Drug: Psilocybin 20
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 20 mg
Study: 37231080
Drug: Mescaline 300
Normalized name: Mescaline
DrugBank: Mescaline (DB19083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mescaline 300 mg
Study: 37231350
Drug: Lu AG09222
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AG09222 + PACAP38 infusion
Study: 37231350
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + PACAP38 infusion
Study: 37231477
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (oral information and brochures)
Study: 37231479
Drug: Pre-release extended-release
Normalized name: ascorbic acid / folic acid Extended Release Oral Tablet [Pre Folic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-release extended-release naltrexone (XR-NTX) + referral to community XR-NTX